Short Interest in Prenetics Global Limited (NASDAQ:PRE) Declines By 17.6%

Prenetics Global Limited (NASDAQ:PRE) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 32,800 shares, a decrease of 17.6% from the February 13th total of 39,800 shares. Based on an average daily volume of 13,600 shares, the days-to-cover ratio is presently 2.4 days. Currently, 0.4% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $9.00 price objective on shares of Prenetics Global in a report on Thursday, January 16th.

Prenetics Global Stock Down 0.4 %

Prenetics Global stock traded down $0.02 during midday trading on Thursday, hitting $4.23. 566 shares of the stock were exchanged, compared to its average volume of 38,882. Prenetics Global has a 52-week low of $2.85 and a 52-week high of $7.84. The business’s 50-day moving average price is $5.24 and its 200-day moving average price is $4.96. The stock has a market capitalization of $51.57 million, a price-to-earnings ratio of -1.06 and a beta of -0.31.

Institutional Investors Weigh In On Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in Prenetics Global Limited (NASDAQ:PRE) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.